Tonix announces $4.4M offering at $0.30 per share; lowers existing warrant exercise prices to $0.33

Tonix Pharmaceuticals Holding Corp.

Gross proceeds of ~$4.4M from sale of 14.7M shares and 14.7M Series E warrants at $0.30 combined price.
Series E warrants exercisable at $0.33, begin 6 months from issuance, expire in 5.5 years.
Existing warrants from Aug/Oct/Dec 2023 amended to exercise price $0.33 and extended expiration dates, subject to shareholder approval.
Proceeds to be used for working capital, general corporate purposes, and to satisfy a portion of debt.
Closing expected April 1, 2024; A.G.P./Alliance Global Partners acts as placement agent with 7% fee.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Purchase Agreement with certain institutional investors valued at up to approximately $4.4 million (effective 2024-03-28).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: up to approximately $4.4 million
Effective: 2024-03-28

Exact text from the filing

On March 28, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).

View on SEC.gov

438 material agreements filed in the last 30 days. Browse all material agreements →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-24-004225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.